Who Paid My Doc
Cathleen Power
Nurse Practitioner, Primary Care Boston, MA Nurse Practitioner
NPI 1346493673 CMS profile 10680119
44 Binney St, Dana 1234, Boston, MA 02115
General payments
$246
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Cathleen Power of Boston, MA is reported in the CMS Open Payments database as having received $246 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 44th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $246 | 7 |
Beside peers
- Cathleen Power
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Cathleen Power were reported at $0. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Cathleen Power | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $137 | $39–$445 | $132 |
| 2022 | $0 | $139 | $44–$421 | $149 |
| 2023 | $246 | $163 | $53–$481 | $160 |
| 2024 | $0 | $176 | $54–$511 | $164 |
| 2025 | $0 | $169 | $51–$499 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
698
Drug cost
$6,616,164
Branded share of claims
67.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | Brand | 359 | $6,098,493 | |
| Lorbrena Lorlatinib | Brand | 15 | $311,463 | |
| Gilotrif Afatinib Dimaleate | Brand | 12 | $135,089 | |
| Eliquis Apixaban | Brand | 87 | $67,600 | |
| Erlotinib Hcl | Generic | 13 | $942 | |
| Doxycycline Monohydrate | Generic | 36 | $505 | |
| Dexamethasone | Generic | 25 | $318 | |
| Omeprazole | Generic | 15 | $306 | |
| Clindamycin Phosphate | Generic | 13 | $299 | |
| Prochlorperazine Maleate | Generic | 21 | $242 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner, Primary Care in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.